Abstract
Wyeth-Ayerst’s venlafaxine [‘Effexor’] appears to provide better remission rates in patients with depression compared with selective serotonin reuptake inhibitors (SSRIs). These results, from a meta-analysis of 8 clinical studies, were presented at the 11th World Congress of Psychiatry [Hamburg, Germany; August 1999]. Also presented were trials showing that venlafaxine improves cognition in elderly patients with depression compared with dothiepin, and that extended-release (XR) venlafaxine is effective in preventing relapse in patients with depression.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
